Cel-Sci Corporation · AMEX:CVM
Cel-Sci — Investor Presentation (November 2026)
22 slides from Cel-Sci's investor presentation, November 2026
Slide 1: Multikine: A First-In-Class Cancer Immunotherapy
Multikine “A First-In-Class Cancer Immunotherapy” Activating the immune system to fight cancer BEFORE the ravages of surgery, radiation and chemotherapy November 2026 NYSE American: CVM
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Please refer to our public filings for full disclosure. This presentation contains “forward-looking statements” within requirements; the therapeutic benefits and effectiveness of ou
Slide 3: We seek to transform the standard of care by stopping cancer recurrence
We seek to transform the standard of care by stopping cancer recurrence before it starts—administering our immunotherapy drug Multikine before surgery, radiation and chemotherapy—to potentially extend survival. NYSE American: CVM 3
Slide 4: CEL-SCI: U.S. Registration Trial and Saudi Regulatory Pathway
CEL-SCI: U.S. Registration Trial and Saudi Regulatory Pathway ● We are pursuing a dual regulatory and market-entry track in the U.S. and Saudi Arabia. The agreement with our Saudi Arabian Pharma partner includes 50% / 50% revenue share with the goal of commercialization in 2027 or early 2028, pendin
Slide 5: CEL-SCI's Goal: Make the First Cancer Treatment More Successful
CEL-SCI’s Goal: Make the First Cancer Treatment More Successful We do this by giving our We do so because – Multikine helps the body realize immunotherapy drug Multikine this is the time when the that there is a tumor – right after diagnosis, before: immune system is still the unleashing the full po
Slide 6: Multikine Treatment Sequence & Biomarker Discovery
Multikine Treatment Sequence & Biomarker Discovery ● The challenge we had to address was that we give Multikine first, before surgery, but the determination for the addition of chemotherapy is made after surgery based on pathology findings of the resected tumor and lymph nodes. o We had to develop a
Slide 7: The Need for Innovation in Head & Neck Cancer
The Need for Innovation in Head & Neck Cancer Head & neck cancer: $7.68B ● 6th most common cancer Multikine emerges as a beacon of ● ~900,000 newly diagnosed patients per year hope as an investigational ● Global head and neck cancer market: $2.58 billion in 2024, immunotherapy designed to activate p
Slide 8: Market Opportunity: Targeting a Significant Patient Population
Market Opportunity: Targeting a Significant Patient Population o Multikine is poised to address a substantial segment of the head and neck cancer market, particularly patients whose cancer has not yet spread to the lymph nodes (N0) and whose tumors have little or none of the biomarker PD-L1 tumor ex
Slide 9: U.S. Registration Study: Global Enrollment and Regulatory Pathways
U.S. Registration Study*: Global Enrollment and Regulatory Pathways Planned Patient Enrollment in: Partner Territories o U.S. o Taiwan o Select countries in: o Europe o Asia o South America Current partner territories: Amarox in Saudi Arabia and Orient EuroPharma in Taiwan In addition to Saudi Arabi
Slide 10: Amarox – Strategic Partner in Saudi Arabia 50% / 50% Revenue Share
Amarox – Strategic Partner in Saudi Arabia In May 2026, CEL-SCI signed a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine by 2027 or early 2028 pursuant to Vision 2030 ● 50%/50% revenue shari
Slide 11: Multikine Improved Survival in the Completed Phase 3 Study
Multikine Improved Survival in the Completed Phase 3 Study Target Population (No lymph node involvement & PD-L1 low/zero) for U.S. Registration Study ● No safety signals or toxicities vs standard of care ● 5-year survival: 73% (Multikine) vs. 45% Multikine (Control) ● Statistically significant (log
Slide 12: CEL-SCI Phase 3 Results
CEL-SCI Phase 3 Results From survival results to biomarker-defined patient selection, peer-reviewed publications culminate in Keynote Presentation 2023 July 2026 2022 ECHNO • 2024 Oral ASCO ESTRO • ESMO Oncology Phase 3 survival AHNS Refined population Biomarkers for results Deeper Phase 3 + most li
Slide 13: U.S. Registration Study
U.S. Registration Study* One single registration study of 212 patients. We select the patients who showed the best survival in the prior study: same population, but patients must have no cancer spread to lymph nodes and be PD-L1 TPS <10%. ● This study is a repeat, enrolling only the target populatio
Slide 14: The U.S. Registration Study
The U.S. Registration Study* ✓ U.S. Registration Study will ONLY enroll the target biomarker-selected population—as confirmed by biomarkers that are the subject of the Keynote presentation at the 6th World Congress on Otology, Rhinology and Laryngology ✓ The target population demonstrated the follow
Slide 15: Our U.S. Registration Study Design
Our U.S. Registration Study Design* Stage 1: Treatment Period Stage 2: Follow-up period Treatment Arm Multikine treatment first, then standard of care n=106 Randomized 1:1 between the treatment arm and the Assess overall survival as the primary efficacy endpoint, control arm and then histopathology
Slide 16: How Multikine Works: Waking Up the Immune System
How Multikine Works: Waking Up the Immune System Tumors normally try to hide from the immune system. Multikine is injected before surgery to unmask the tumor, waking up the patient's immune system to attack the cancer while the body is still strong. 1 Timing 2 Alarm 3 Attack INJECT BEFORE REACTIVATE
Slide 17: Multikine: Mass-Produced and Non-Toxic
Multikine: Mass-Produced and Non-Toxic 17
Slide 18: Positive Tumor Responses Predict for Survival Across All Patients
Positive Tumor Responses Predict for Survival Across All Patients (n=928) in the Phase 3 Trial After treatment with Multikine and before surgery, tumors are shrinking and cancer is becoming less severe p < 0.005 25% p < 0.005 80% p < 0.005 75% 70% 22% 65% 72% 20% Multikine 60% Multikine 68% Tumor Mu
Slide 19: Even Better Tumor Responses in the Target Population
As Expected, Even Better Tumor Responses in the Target Population (n=114) in the Phase 3 Trial p < 0.009 35% 35% 30% Multikine 25% Response rate 20% p < 0.007 15% 10% 13% 13% Multikine Control 5% 0.0% 0% Pre-surgical reductions: Pre-surgical downstagings: Tumor shrinkage Reduced cancer severity Mult
Slide 20: Manufacturing Readiness: Prepared for Global Supply
Manufacturing Readiness: Prepared for Global Supply An investment of over $200 million has been made into Multikine manufacturing, ensuring that Multikine can be produced at scale to meet anticipated global demand upon potential approval. +$200 M Invested in state-of-the-art facility Barrier to comp
Slide 21: Investment Highlights
Investment Highlights* Strong Phase 3 Survival Multikine demonstrated a 73% five-year overall survival rate in the target head & neck cancer population versus 45% in Benefit the control group, with a hazard ratio of 0.34 (95% CIs [0.18, 0.66]). That is a 66% reduction in the risk of dying. Patients
Slide 22: Thank you!
Thank you! NYSE American: CVM 22